Northwest Wealth Management’s Zevra Therapeutics ZVRA Stock Holding History

Northwest Wealth Management’s Portfolio ZVRA Stock Details ZVRA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-1,317	Closed	-$5K	–	97
2020 Q1	$5K	Buy	1,317 +313	+31%	+$1.73K	0.01%	90
2019 Q4	$6K	Hold	1,004	–	–	0.01%	98
2019 Q3	$11K	Hold	1,004	–	–	0.01%	116
2019 Q2	$28K	Hold	1,004	–	–	0.02%	115
2019 Q1	$27K	Hold	1,004	–	–	0.02%	273
2018 Q4	$29K	Hold	1,004	–	–	0.02%	249
2018 Q3	$77K	Hold	1,004	–	–	0.06%	181
2018 Q2	$104K	Sell	1,004 -292	-23%	-$28.5K	0.08%	146
2018 Q1	$164K	Buy	1,296 +292	+29%	+$28.2K	0.12%	118
2017 Q4	$65K	Buy	+1,004	New	+$60.6K	0.05%	91
2017 Q3	–	Sell	-1,296	Closed	-$83K	–	95
2017 Q2	$83K	Hold	1,296	–	–	0.08%	94
2017 Q1	$102K	Hold	1,296	–	–	0.09%	91
2016 Q4	$61K	Buy	+1,296	New	+$79.6K	0.06%	88

Other funds holding ZVRA

AWA

Arete Wealth Advisors Chicago, Illinois $1.33B AUM 25.12% 1-Year Est. Return

BBVA

Banco Bilbao Vizcaya Argentaria Madrid, Spain $14.3B AUM 26.23% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

ISB

Iowa State Bank Urbandale, Iowa $543M AUM 21.44% 1-Year Est. Return

Carson Wealth (CWM LLC) Omaha, Nebraska $38.1B AUM 19.66% 1-Year Est. Return

Rockefeller Capital Management New York $56.4B AUM 24.96% 1-Year Est. Return

Northwest Wealth Management's ZVRA Position: Q2 2020 in Review

Northwest Wealth Management sold out of Zevra Therapeutics (ZVRA) in Q2 2020, closing a stake of 1,317 shares — an estimated $5K sold.

Northwest Wealth Management first reported a position in ZVRA in Q4 2016 and held it in 13 quarters. The position peaked at $164K in Q1 2018. 6 funds tracked by Wall St. Rank hold ZVRA as of Q2 2020.

Northwest Wealth Management reported no remaining Zevra Therapeutics position as of Q2 2020 after selling out during the quarter.
Northwest Wealth Management sold 1,317 Zevra Therapeutics shares in Q2 2020, an estimated $5K.
Northwest Wealth Management first reported a position in Zevra Therapeutics in Q4 2016 and held it in 13 quarters.
Northwest Wealth Management's Zevra Therapeutics position peaked at $164K in Q1 2018.
6 funds tracked by Wall St. Rank held Zevra Therapeutics as of Q2 2020.

Based on Northwest Wealth Management's 13F filing for Q2 2020, filed 13 Jul 2020.